The disclosure provides compositions and methods involving viral RNA segments for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.

The disclosure provides compositions and methods involving viral RNA segments for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The present disclosure is drawn to compositions, methods, and systems for loop-mediated isothermal amplification (LAMP) analysis on a solid phase medium. The composition can comprise one or more target primers, a DNA polymerase, and a re-solubilization agent. The composition can be substantially free of non-pH sensitive agents capable of discoloring the solid phase medium. The method can comprise providing an assembly of a solid phase medium, depositing a biological sample onto the solid phase medium, and heating the assembly to an isothermal temperature sufficient to facilitate a LAMP reaction. The system can comprise a composition and a solid phase medium on to which the composition is deposited.

The present disclosure is drawn to compositions, methods, and systems for loop-mediated isothermal amplification (LAMP) analysis on a solid phase medium. The composition can comprise one or more target primers, a DNA polymerase, and a re-solubilization agent. The composition can be substantially free of non-pH sensitive agents capable of discoloring the solid phase medium. The method can comprise providing an assembly of a solid phase medium, depositing a biological sample onto the solid phase medium, and heating the assembly to an isothermal temperature sufficient to facilitate a LAMP reaction. The system can comprise a composition and a solid phase medium on to which the composition is deposited.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L.sub.1-X.sub.n—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L.sub.1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

A cell line of Accession No. NITE P-03458. A producing method of a cell line includes: a transfection step of transfecting a vector into a cell, where the vector includes a nucleic acid sequence encoding a nonstructural protein of a coronavirus, a reporter protein including a drug-resistant protein, and a structural protein of the coronavirus; and a selection step of performing selection on the cell obtained in the transfection step using a drug.

A cell line of Accession No. NITE P-03458. A producing method of a cell line includes: a transfection step of transfecting a vector into a cell, where the vector includes a nucleic acid sequence encoding a nonstructural protein of a coronavirus, a reporter protein including a drug-resistant protein, and a structural protein of the coronavirus; and a selection step of performing selection on the cell obtained in the transfection step using a drug.

Filovirus glycoprotein mutations that stabilize the trimeric form of the glycoprotein are provided. The Filovirus glycoproteins have certain amino acid substitutions at specified positions in the glycoprotein sequence. The Filovirus glycoproteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to a Filovirus glycoprotein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the Filovirus glycoproteins, as well as compositions containing the Filovirus glycoproteins, nucleic acid, and vectors.